Harvard Medical School
Department of Population Medicine
401 Park Drive, Suite 401
Boston, MA 02215
Phone: (617) 867-4942
Fax: (617) 867-4276
Stephen Soumerai, ScD
Stephen B. Soumerai is Professor of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute, where he directs the Drug Policy Research Group, a research and fellowship training program focused on pharmaceutical outcomes and quality of health care which is also a World Health Organization Collaborating Center in Pharmaceutical Policy. He also co-chairs the Statistics and Evaluative Sciences concentration within Harvard University’s health policy Ph.D. program. Dr. Soumerai has led or been a member of numerous NIH and international advisory and peer review committees for prioritizing and funding health policy research. He recently served as International Trustee for the Canadian Health Services Research Foundation. Dr. Soumerai is the recipient of numerous honors including several article of the year awards from national and international scientific societies, named lectureships, and the Everett Mendelsohn Excellence in Mentoring Award from the Harvard University Graduate School of Arts and Sciences.
Dr. Soumerai has published more than 250 original scientific articles in leading scientific journals, such as the New England Journal of Medicine and the Journal of the American Medical Association. He is well known nationally and internationally for his work on the impacts of health policies and methods to improve the quality of medical practice. His recent research has focused on cost-related underuse of medications; as well as the impacts of drug coverage and cost-containment policies on access to effective medications, quality and costs of care and clinical outcomes among vulnerable populations, and the unintended health outcomes of FDA warnings regarding use of antidepressants in children. He frequently advises Congress, state legislatures, and federal and international agencies on the design of drug cost containment, coverage and quality-of-care policies, and evidence-based health policy. His research has been used extensively to support expanded economic access to medications in Medicaid and Medicare.
Dr. Soumerai has published numerous op-eds in leading news outlets, including The Wall Street Journal, The Washington Post, Newsweek, The Huffington Post, and The Boston Globe on subjects including elimination of coverage gaps in the Medicare drug benefit, adverse consequences of rushed nationwide implementation of health IT, undertreatment of pain, required drug coverage in Massachusetts health reform plans, state censorship of health research, poor efficacy of pay-for-performance policies, and arbitrary economic penalties for hospital readmissions.
- Serumaga B, Ross-Degnan D, Avery AJ, Elliott RA, Majumdar SR, Zhang F, Soumerai SB. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ. 2011 Jan 25. [Epub ahead of print].
- Briesacher BA, Ross-Degnan D, Wagner AK, Fouayzi H, Zhang F, Gurwitz JH, Soumerai SB. Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy. Med Care. 2010 Jun;48(6):503-9.
- Briesacher BA, Soumerai SB, Field TS, Fouayzi H, Gurwitz JH. Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med. 2010 Apr 26;170(8):693-8.
- Madden JM, Graves AJ, Ross-Degnan D, Briesacher BA, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. JAMA. 2009 Oct 28;302(16):1755-6.
- Law MR, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ. 2008 Sep 2;337:a1055.
- Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law MR, Hughes TE, Chapman D, Adams AS. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008 May-Jun;27(3):w185-95. Epub 2008 May 1.
- Zhang Y, Soumerai SB. Do newer prescription drugs pay for themselves? A reassessment of the evidence. Health Aff (Millwood). 2007 May-Jun;26(3):880-6.
- Wharam JF, Landon BE, Galbraith AA, Kleinman KP, Soumerai SB, Ross-Degnan D. Emergency department use and subsequent hospitalizations among members of a high-deductible health plan. JAMA. 2007 Mar 14;297(10):1093-102.
- Wagner AK, Ross-Degnan D, Gurwitz JH, Zhang F, Gilden DB, Cosler L, Soumerai SB. Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med. 2007 Jan 16;146(2):96-103.
- Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14;346(11):822-9.
- Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000 Jun 1;342(22):1645-50.
- Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees--a call to action. N Engl J Med. 1999 Mar 4;340(9):722-8.
- Soumerai SB, McLaughlin TJ, Gurwitz JH, Guadagnoli E, Hauptman PJ, Borbas C, Morris N, McLaughlin B, Gao X, Willison DJ, Asinger R, Gobel F. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA. 1998 May 6;279(17):1358-63.
- Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". N Engl J Med. 1983 Jun 16;308(24):1457-63.